NCT04908683: A reported trial by Janssen Vaccines & Prevention B.V.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04908683 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 21, 2021 |
| Completion date | July 21, 2023 |
| Required reporting date | July 20, 2024, midnight |
| Actual reporting date | Dec. 21, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |